clinical trial · NCT06619587
A Study to Evaluate Safety, Pharmacokinetics, and Activity of GDC-7035 as a Single Agent and in Combination in Patients With Advanced Solid Tumors
Genentech, Inc.·phase1·recruiting·n = 410
Solid TumorPhase I Arm APhase I Arm B
brief summary
This is a first-in-human Phase I/II, open-label, multicenter, dose-escalation and expansion study designed to evaluate the safety, pharmacokinetics, and preliminary activity of GDC-7035 as a single agent and in combination with other anti-cancer therapies in participants with advanced or metastatic solid tumors that harbor the KRAS G12D mutation.
started
Nov 14, 2024
primary completion
May 31, 2028
completion
May 31, 2028
last updated
Jun 1, 2026
official title
A Phase I/II Dose-Escalation and Expansion Study Evaluating the Safety, Pharmacokinetics, and Activity of GDC-7035 as a Single Agent and in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors With a KRAS G12D Mutation
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol